This article is more than 5 years old. Information may no longer be current.
Nicox, Bausch + Lomb co-promote latanoprostene bunod
Click Here to Manage Email Alerts
Nicox announced it has notified Bausch + Lomb of its decision to co-promote the glaucoma and ocular hypertension treatment, latanoprostene bunod, in the U.S., according to the terms of their worldwide licensing agreement from March 2010.
The press release from Nicox stated that the treatment is in phase 3 clinical development and was licensed by Nicox to Bausch + Lomb in 2010.
The phase 3 clinical program includes two studies: APOLLO and LUNAR. Valeant Pharmaceuticals, of which Bausch + Lomb is a division, anticipates the first round of results in the third quarter of this year and from the second of these studies in the fourth quarter, Nicox announced.
The clinical programs are designed to compare the efficacy and safety of latanoprostene bunod administered once daily with timolol maleate 0.5% administered twice daily in lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.